Torrent Pharmaceuticals Limited has once again expanded its recall of Losartan potassium tablets and Losartan potassium/hydrochlorothiazide tablets, the Food and Drug Administration announced Thursday.
The company has added an additional 36 lots of Losartan potassium tablets and 68 lots of Losartan potassium/hydrochlorothiazide tablets.
The recall is due once again to an impurity called N-Methylnitrosobutric acid or NMBA.
The recalled lots have more NMBA than what is acceptable for daily intake set by the FDA.
Consumers with medical questions connected to the recall are being instructed to call Torrent Pharmaceuticals at 1-800-912-9561 or email Medinfo.Torrent@apcerls.com.
For more information, including the complete list of batch numbers included with the recall’s expansion, click here.
Thank you for reading the Dayton Daily News and for supporting local journalism. Subscribers: log in for access to your daily ePaper and premium newsletters.
Thank you for supporting in-depth local journalism with your subscription to the Dayton Daily News. Get more news when you want it with email newsletters just for subscribers. Sign up here.